Magnolia Capital Advisors’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $877K | Sell |
11,215
-606
| -5% | -$47.4K | 0.22% | 115 |
|
|
2025
Q1 | $857K | Buy |
11,821
+1,400
| +13% | +$101K | 0.23% | 109 |
|
|
2024
Q4 | $771K | Buy |
10,421
+3,776
| +57% | +$280K | 0.2% | 117 |
|
|
2024
Q3 | $439K | Buy |
6,645
+60
| +0.9% | +$3.96K | 0.22% | 100 |
|
|
2024
Q2 | $608K | Buy |
+6,585
| New | +$608K | 0.34% | 78 |
|
|
2024
Q1 | – | Sell |
-6,911
| Closed | -$511K | – | 107 |
|
|
2023
Q4 | $511K | Buy |
+6,911
| New | +$511K | 0.37% | 68 |
|
|
2023
Q2 | – | Sell |
-5,459
| Closed | -$452K | – | 132 |
|
|
2023
Q1 | $452K | Buy |
5,459
+413
| +8% | +$34.2K | 0.23% | 98 |
|
|
2022
Q4 | $376K | Sell |
5,046
-104
| -2% | -$7.75K | 0.25% | 98 |
|
|
2022
Q3 | $426K | Buy |
5,150
+150
| +3% | +$12.4K | 0.36% | 78 |
|
|
2022
Q2 | $475K | Buy |
5,000
+715
| +17% | +$67.9K | 0.43% | 74 |
|
|
2022
Q1 | $504K | Buy |
4,285
+51
| +1% | +$6K | 0.2% | 110 |
|
|
2021
Q4 | $549K | Buy |
4,234
+213
| +5% | +$27.6K | 0.16% | 110 |
|
|
2021
Q3 | $455K | Buy |
+4,021
| New | +$455K | 0.16% | 119 |
|
|
2021
Q2 | – | Sell |
-3,765
| Closed | -$315K | – | 148 |
|
|
2021
Q1 | $315K | Buy |
+3,765
| New | +$315K | 0.62% | 58 |
|